Alexandria Venture Investments
VC Fund
Pasadena, United States
Alexandria Venture Investments is a venture capital firm that develops work in real estate technology, and healthcare sectors. The company's strategic venture capital platform is Alexandria Venture Investments. Since its inception in 1996, the company has invested in disruptive life science, agrifood tech, and technology companies that aredeveloping transformative new modalities and platforms to meaningfully improve human health.
- Total investments:
- 270
- Last investment:
- Lead investor:
- 7%
Last updated:
For AI agents: llms.txt
Industries Alexandria Venture Investments invests in
Stages Alexandria Venture Investments invests in
Countries Alexandria Venture Investments invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $2M–$31M
- Series A
- $12M–$100M
- Series B
- $25M–$150M
Investment Focus
Industry
- Biotechnology 167 (62%)
- Health Care 84 (31%)
- Therapeutics 76 (28%)
- Medical 51 (19%)
- Life Science 44 (16%)
Stage
- Series A 84 (31%)
- Series B 58 (21%)
- Seed 25 (9%)
- Series C 25 (9%)
- Funding Round 16 (6%)
Country
- United States 169 (63%)
- Canada 4 (1%)
- France 4 (1%)
- Switzerland 2 (1%)
- China 1 (0%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Daniel J. Ryan
Co-Chief Investment Officer & Regional Market Director –San Diego
|
Co-Chief Investment Officer & Regional Market Director –San Diego | Total investments: 0 | Find email | |
Dean A. Shigenaga
Co-President & Chief Financial Officer
|
Co-President & Chief Financial Officer | Total investments: 0 | Find email | |
Joel Marcus
Executive Chairman & Founder
|
Executive Chairman & Founder | Total investments: 8 | Find email | |
Peter M. Moglia
Co-Chief Executive Officer
|
Co-Chief Executive Officer | Total investments: 0 | Find email | |
Stephen A. Richardson
Co-Chief Executive Officer
|
Co-Chief Executive Officer | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Triveni Bio
|
Triveni Bio is at the forefront of human genetics, cutting-edge antibody design, and precision medicine, pioneering the identification of new disease targets. | $65M / Series C / Jun 17, 2026 | |
Vedana Therapeutics
|
Vedana Therapeutics is a Seattle biotechnology company developing next-generation antibody therapies for migraine prevention. | $46M / Series A / Jun 17, 2026 | |
CREATE Medicines
|
Myeloid Therapeutics is an immunology company focused on combining immunologic insights with cutting-edge technologies to harness myeloid cells to eradicate cancer and other diseases. The Company's ATAKTM platform technology can be broadly applied, and it is initially advancing a cell therapy program for T cell lymphoma and a primed monocyteapproach to treat glioblastoma. The ATAK platform is scalable to multiple treatment modalities and other disease areas in collaboration with partners. | $122M / Series B / May 14, 2026 | |
Fathom Therapeutics
|
Fathom Therapeutics, previously known as Atommap, is a biotechnology company focused on designing therapeutic molecules through computational drug discovery approaches. The company develops models that simulate biomolecular and protein motion to better understand how proteins behave and interact, enabling the identification of new therapeuticstrategies. Its platform combines generative design, predictive modeling, and computational assays to create and evaluate molecular candidates for their binding affinity and functional effects. By leveraging these simulations, it supports drug discovery processes such as hit identification, lead optimization, and the design of targeted molecules, including degraders and molecular glues. The company also collaborates with partners by providing molecular designs, predictive insights, and co-development opportunities for advancing therapeutic candidates. | $47M / Series A / Apr 27, 2026 | |
Alloy Therapeutics
|
Alloy Therapeutics makes medicine by democratizing access to foundational drug discovery platforms and services. Alloy-Gx, its first platform, is a royalty-free suite of immunocompetent transgenic mice enabling best-in-class in vivo human antibody discovery. Founded in 2017, Alloy Therapeutics is headquartered in Lexington, Massachusetts. | $40M / Series E / Apr 15, 2026 | |
Neomorph
|
Neomorph is building a leading protein degradation entity, focused on “molecular glue” degraders. Its mission is to use this technology to solve critical problems in human health with the discovery and development of innovative new medicines against “undruggable targets.” | $100M / Series B / Apr 13, 2026 | |
Sidewinder Therapeutics
|
Sidewinder Therapeutics develops bispecific antibody-drug conjugates (ADCs) aimed at treating solid tumors. Their mission is to create life-saving therapies through precision therapeutics. | $137M / Series B / Apr 08, 2026 | |
TRex Bio
|
TRexBio is a discovery stage biotechnology company leveraging cutting-edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop revolutionary therapeutics for cancer and inflammatory diseases. Our powerful ‘deep biology’ discovery engine maps human tissue Treg behavior to disease processes, allowing us toidentify and characterize novel targets for therapeutic intervention. Leveraging this platform, we are building a broad portfolio of novel therapies that modulate the immune system to restore human tissue immune homeostasis. | $50M / Jan 27, 2026 | |
Proxima
|
Proxima Bio develops programmable medicines that modulate protein interactions to address disease processes. It focuses on creating proximity-modulating therapeutics that direct protein interactions for potential use in conditions such as autoimmune disorders and cancer, expanding the range of targets that traditional drugs cannot easily reach.Proxima Bio combines structural biology, data generation, and machine learning to identify actionable protein-protein interfaces and support the discovery of new therapeutic modalities. The company works with pharmaceutical partners to apply its platform in research collaborations and advance drug discovery pipelines. Proxima Bio’s platform integrates multiple technologies to support the design and discovery of novel proximity-based treatment approaches. | $86.3M / Seed / Jan 13, 2026 | |
Precede Biosciences
|
Precede Biosciences is breaking down the barriers to precision medicine by redefining what can be gleaned from a simple blood draw. Precede aims to increase drug development success rates and to contribute to a future in which every patient can receive a speedy, minimally invasive diagnosis and therapy tailored to the biology of their condition. | $63.5M / Series B / Jan 12, 2026 | |
| See all 270 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Alexandria Venture Investments invest in?
Alexandria Venture Investments invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 270 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Alexandria Venture Investments's check size?
Alexandria Venture Investments typically joins rounds of $2M–$31M at Seed, $12M–$100M at Series A and $25M–$150M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Alexandria Venture Investments participates in.
How do I contact Alexandria Venture Investments?
Public channels for Alexandria Venture Investments include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Alexandria Venture Investments?
The team at Alexandria Venture Investments includes Daniel J. Ryan (Co-Chief Investment Officer & Regional Market Director –San Diego), Dean A. Shigenaga (Co-President & Chief Financial Officer) and Joel Marcus (Executive Chairman & Founder). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
